Bikunin (Urinary Trypsin Inhibitor): Structure, Biological Relevance, And Measurement

Advances in Clinical Chemistry

Volumn 44, Issue , 2007, Pages 223-245

  Pugia, Michael J ^a   Valdes Jr , Roland ^b   Jortani, Saeed A ^b  

^a SIEMENS CORPORATE RESEARCH   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; TRYPSIN INHIBITOR; ULINASTATIN;

AMINO ACID SEQUENCE; APOPTOSIS; BIOSYNTHESIS; CARBOHYDRATE ANALYSIS; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; INFLAMMATION; METABOLISM; MOLECULAR GENETICS; PATHOPHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; APOPTOSIS; CARBOHYDRATE SEQUENCE; GLYCOPROTEINS; HUMANS; INFLAMMATION; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; SIGNAL TRANSDUCTION; TRYPSIN INHIBITORS;

EID: 34347204795     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2423(07)44007-0     Document Type: Review

References (105)

1. Bauer J., and Reich III Z. Antitryptic action of urine. Med Klin 5 (1909) 1744-1747
2. Faarvang H. Urinary trypsin inhibitor in man. Scand J Clin Lab Invest 120 (1965) 1-83
3. Fries E., and Blom A. Bikunin-not just a plasma proteinase inhibitor. Int J Biochem Cell Biol 32 (2000) 125-137
4. Pugia M., and Lott J. Pathophysiology and diagnostic value of urinary trypsin inhibitors (review). Clin Chem Lab Med 43 (2005) 1-16
5. Kato K. Human urinary trypsin inhibitor: Its structure, biochemical properties and biosynthesis. Igaku Yakugaku 33 (1995) 1089-1097
6. Bost F., Diarra-Mehrpour M., and Martin J. Inter-alpha-trypsin inhibitor proteoglycan family-a group of proteins binding and stabilizing the extracellular matrix. Eur J Biochem 252 (1998) 339-346
7. Fries E., and Kaczmarczyk A. Inter-alpha-inhibitor, hyaluronan and inflammation. Acta Biochim Pol 50 (2003) 735-742
8. Salier J., Rouet P., Raguenez G., and Daveau M. The inter-alpha-inhibitor family: From structure to regulation. Biochem J 315 (1996) 1-9
9. Pratt C., Swaim M., and Pizzo S. Inflammatory cells degrade inter-alpha-inhibitor to liberate urinary proteinase inhibitors. J Leukoc Biol 45 (1989) 1-9
10. Mizon C., Piva F., Queyrel V., Balduyck M., Hachulla E., and Mizon J. Urinary bikunin determination provides insight into proteinase/proteinase inhibitor imbalance in patients with inflammatory diseases. Clin Chem Lab Med 40 (2002) 579-586
11. Thogersen I., and Enghild J. Biosynthesis of bikunin proteins in human carcinoma cell line HepG2 and in primary human hepatocytes. J Biol Chem 270 (1995) 18700-18709
12. Vetr H., and Gebhard W. Structure of the human alpha-1-microglobulin-bikunin gene. Biol Chem Hoppe Seyler 371 (1990) 1185-1196
13. Zhu Z., Valdes R., Simmons C., Linder M., Pugia M., and Jortani S. Analysis of ligand binding by bioaffinity mass spectrometry. Clin Chim Acta 371 1-2 (2006) 71-78
14. Pugia M., Jortani S., Basu M., Sommer R., Kuo H., Murphy S., et al. Immunological evaluation of urinary trypsin inhibitors in blood urine: Role of N- & O-linked glycoproteins. Glycoconj J 24 1 (2006) 5-15
15. Pugia M., Sommer R., Corey P., Lott J., Anderson L., Gleason S., et al. The uristatin dipstick is useful in distinguishing upper respiratory from urinary tract infections. Clin Chim Acta 341 (2004) 73-81
16. Brinkmann T., Weilke C., and Kleesiek K. Recognition of acceptor proteins by UDP-d-xylose proteoglycan core protein b-d-xylosyltransferase. J Biol Chem 272 (1997) 11171-11175
17. Pugia M., Sommer R., Volkir P., Jortani S., Valdes R., and Lott J. Serine protease inhibitors as markers of inflammation in atheroscolerosis (2005) Siemens Medical Solution Internal Data Report 2005 (submitted for publication).
18. Pugia M., Takemura T., Kuwajima S., Suzuki M., Cast T., Profit J., et al. Clinical utility of a rapid test for uristatin. Clin Biochem 35 (2002) 105-110
19. Jortani S., Pugia M., Elin R., Thomas M., Womack E., Cast T., et al. Sensitive noninvasive marker for diagnosis of probable bacterial or viral infection. J Clin Lab Anal 18 (2004) 289-295
20. Lindstroem K., Blom A., Johnsson E., Haraldsson B., and Fries E. High glomerular permeability of bikunin despite similarity in charge and hydrodynamic size to serum albumin. Kidney Int 51 (1997) 1053-1058
21. Joberg M., Blom A., Larsson B., Alston-Smith J., Mats S., and Fries E. Plasma clearance of rat bikunin: Evidence for receptor-mediated uptake. Biochem J 308 (1995) 881-887
22. Ohlson M., Sorensson J., Lindstrom K., Blom A., Fries E., and Haraldsson B. Effects of filtration rate on the glomerular barrier and clearance of four differently shaped molecules. Am J Physiol 281 (2001) F103-F113
23. Kobayashi H., Gotoh J., Hirashima Y., and Terao T. Inter-alpha-trypsin inhibitor bound to tumor cells is cleaved into the heavy chains and the light chain on the cell surface. J Biol Chem 271 (1996) 11362-11367
24. Janssen U., Thomas G., Glant T., and Phillips A. Expression of inter-alpha-trypsin inhibitor and tumor necrosis factor-stimulated gene 6 in renal proximal tubular epithelial cells. Kidney Int (2001) 60126-60136
25. Selbi W., de la Motte C., Hascall V., Day A., Bowen T., and Phillips A. Characterization of hyaluronan cable structure and function in renal proximal tubular epithelial cells. Kidney Int 70 7 (2006) 1287-1295
26. Rose T., and Di Cera E. Substrate recognition drives the evolution of serine proteases. J Biol Chem 277 (2002) 19243-19246
27. Perona J., and Craik C. Structural basis of substrate specificity in the serine proteases. Protein Sci 4 (1995) 337-360
28. Delaria K., Muller D., Marlor C., Brown J., Das R., Roczniak S., et al. Characterization of placental bikunin, a novel human serine protease inhibitor. J Biol Chem 272 (1997) 12209-12214
29. Kingston B., and Anderson S. Sequences encoding two trypsin inhibitors occur in strikingly similar genomic environments. Biochem J 233 (1986) 443-450
30. Yamasaki F., Tomoaki S., Watanabe M., and Mizota M. Uptake of human urinary trypsin inhibitor by the kidney epithelial cell line, LLC-PK1. Pflugers Arch 433 (1996) 9-15
31. Hochstrasser K., Wachter E., and Bretzel G. Liberation of Kunitz-type inhibitors from the inter-alpha-trypsin-inhibitor by limited proteolysis. Proc FEBS 47 (1977) 225-234
32. Zhuo L., Salustri A., and Kimata K. A physiological function of serum proteoglycan bikunin: The chondroitin sulfate moiety plays a central role. Glycoconj J 19 (2002) 241-247
33. Hochstrasser K., Schoenberger O., Rossmanith I., and Wachter E. Kunitz-type proteinase inhibitors derived by limited proteolysis of the inter-alpha-trypsin inhibitor. V. Attachments of carbohydrates in the human urinary trypsin inhibitor isolated by affinity chromatography. Hoppe Seylers Z Physiol Chem 362 (1981) 1357-1362
34. Xu Y., Carr P., Guss J., and Ollis D. The crystal structure of bikunin from the inter-α-inhibitor complex: A serine protease inhibitor with two kunitz domains. J Mol Biol 276 (1998) 955-966
35. Krowarsch D., and Otlewski J. Amino-acid substitutions at the fully exposed P1 site of bovine pancreatic trypsin inhibitor affect its stability. Protein Sci 10 (2001) 715-724
36. Moczydlowski E., Moss G., and Lucchesi K. Bovine pancreatic trypsin inhibitor as a probe of large conductance Ca2+-activated K+ channels at an internal site of interaction. Biochem Pharmacol 43 (1992) 21-28
37. Grzesiak A., Krokoszynska I., Krowarsch D., Buczek O., Dadlez M., and Otlewski J. Inhibition of six serine proteinases of the human coagulation system by mutants of bovine pancreatic trypsin inhibitor. J Biol Chem 275 (2000) 33346-33352
38. Kato Y., Kudo M., Shinkawa T., Mochizuki H., Isaji M., Shiromizu I., et al. Role of O-linked carbohydrate of human urinary trypsin inhibitor on its lysosomal membrane-stabilizing property. Biochem Biophys Res Commun 243 (1998) 377-383
39. Kobayashi H., Sugino D., and Terao T. Urinary trypsin inhibitor, a Kunitz-type protease inhibitor, modulates tumor necrosis factor-stimulated activation and translocation of protein kinase C in U937 cells. Int J Oncol 12 (1998) 95-105
40. Kobayashi H., Sugino D., She M., Ohi H., Hirashima Y., Shinohara H., et al. A bifunctional hybrid molecule of the amino-terminal fragment of urokinase and domain II of bikunin efficiently inhibits tumor cell invasion and metastasis. Eur J Biochem 253 (1998) 817-826
41. Hirashima Y., Kobayashi H., Suzuki M., Tanaka Y., Kanayama N., Fujie M., et al. Characterization of binding properties of urinary trypsin inhibitor to cell-associated binding sites on human chondrosarcoma cell line HCS-2/8. J Biol Chem 276 (2001) 13650-13656
42. Kanayama N., Maehara K., Suzuki M., Fujise Y., and Terao T. The role of chondroitin sulfate chains of urinary trypsin inhibitor in inhibition of LPS-induced increase of cytosolic free Ca2+ in HL60 cells and HUVEC cells. Biochem Biophys Res Commun 238 (1997) 560-564
43. Milner C., and Day A. TSG-6: A multifunctional protein associated with inflammation. J Cell Sci 116 (2003) 1863-1873
44. Mizon C., Mairie C., Balduyck M., Hachulla E., and Mizon J. The chondroitin sulfate chain of bikunin-containing proteins in the inter-alpha-inhibitor family increases in size in inflammatory diseases. Eur J Biochem 268 (2001) 2717-2724
45. Mizon J., Capon C., Mizon C., Lemoine J., and Rodié-Talbère P. In acute inflammation, the chondroitin-4 sulphate carried by bikunin is not only longer; it is also undersulphated. Biochimie 85 (2003) 101-107
46. Yamada S., Oyama M., Yuki Y., Kato K., and Sugahara K. The uniform galactose 4-sulfate structure in the carbohydrate-protein linkage region of human urinary trypsin inhibitor. Eur J Biochem 233 (1995) 687-693
47. Enghild J., Thøgersen I., Cheng F., Fransson L., Roepstorff P., and Rahbek-Nielsen H. Organization of the inter-α-inhibitor heavy chains on the chondroitin sulfate originating from Ser10 of bikunin: Posttranslational modification of IαI derived bikunin. Biochemistry 38 (1999) 11804-11813
48. Mania-Pramanik J., Potdar S., Vadigoppula A., and Sawant S. Elastase: A predictive marker of inflammation and/or infection. J Clin Lab Anal 18 (2004) 153-158
49. Johnson R., Couser W., Alpers C., Vissers M., and Schulze M. The human neutrophils serine proteinases, elastase and cathespin G can mediate glomerular injury in vivo. J Exp Med 168 (1988) 1169-1174
50. Nakatani K., and Takeshita S. Vascular endothelial cell injury by activated neutrophil and treatment for the injury. Surg Trauma Immunol Respon 8 (1999) 112-114
51. Wiedow O., and Meyer-Hoffert U. Neutrophil serine proteases: Potential key regulators of cell signalling during inflammation. J Intern Med 257 (2005) 319-328
52. Afshar-Kharghan V., and Thiagarajan P. Leukocyte adhesion and thrombosis. Curr Opin Hematol 13 (2006) 34-39
53. Trapani J. Granzymes: A family of lymphocyte granule serine proteases. Genome Biol 2 (2001) 30141-30147
54. Kam C., Hudig D., and Powers J. Granzymes (lymphocyte serine proteases): Characterization with natural and synthetic substrates and inhibitors. Biochim Biophys Acta 1477 (2000) 307-323
55. Afshar-Kharghan V., and Thiagarajan P. Leukocyte adhesion and thrombosis. Curr Opin Hematol 13 (2006) 34-39
56. Wiedow O., and Meyer-Hoffert U. Neutrophil serine proteases: Potential key regulators of cell signalling during inflammation. J Intern Med 257 (2005) 319-328
57. Wilharm E., Parry M., Friebel R., Tschesche H., Matschineri G., Sommerhoffi C., et al. Generation of catalytically active granzyme K from Escherichia coli inclusion bodies and identification of efficient granzyme K inhibitors in human plasma. J Biol Chem 274 (1999) 27331-27337
58. Payne V., and Kam P. Mast cell tryptase: A review of its physiology and clinical significance. Anaesthesia 59 (2004) 695-703
59. Brinkmann T., Schaefers J., Guertler L., Kido H., Niwa Y., Katunuma N., et al. Inhibition of tryptase TL2 from human T4+ lymphocytes and inhibition of HIV-1 replication in H9 cells by recombinant aprotinin and bikunin homologs. J Protein Chem 16 (1997) 651-660
60. Cocks T., and Moffatt J. Protease-activated receptors: Sentries for inflammation. Trends Pharmacol Sci 21 (2000) 103-108
61. Nii A., Morishita H., Hirose J., Yamakawa T., and Kanamori T. Novel blood coagulation factor inhibitory activities of the second domain of urinary trypsin inhibitor and its variants. Nippon Kessen Shiketsu Gakkaishi 6 (1995) 203-207
62. Nii A., Morishita H., Yamakawa T., Matsusue T., Hirose J., Miura T., et al. Design of variants of the second domain of urinary trypsin inhibitor (R-020) with increased factor Xa inhibitory activity. J Biochem (Tokyo) 115 (1994) 1107-1112
63. Egeblad K., and Astrup T. Fibrinolysis and the trypsin inhibitor in human urine. Scand J Clin Lab Invest 18 (1966) 181-190
64. Shinohara H., Kobayashi H., Hirashima Y., Ohi H., and Terao T. Urinary trypsin inhibitor (UTI) efficiently inhibits tumor cell invasion and metastasis in the experimental and spontaneous model. J Jpn Soc Cancer Ther 3 (1996) 186-195
65. Campbell D. Towards understanding the kallikrein-kinin system: Insights from measurement of kinin peptides. Braz J Med Biol Res 33 (2000) 665-677
66. Campbell D. The kallikrein-kinin system in humans. Clin Exp Pharmacol Physiol 28 (2001) 1060-1065
67. Imokawa H. Substances influencing the vascular permeability of an ear burn model in mice. The effectiveness of antihistamines. Sei Marianna Ika Daigaku Zasshi 19 (1991) 310-317
68. Imokawa H., Ando K., Kubota T., Isono E., Inoue H., and Ishida H. Study on the kinetics of bradykinin level in the wound produced by thermal injury in the ear burn model in mice. Nippon Yakurigaku Zasshi 99 (1992) 445-450
69. Takada K., Komori M., Notoya A., Tomizawa Y., and Ozaki M. Effect of ulinastatin on microcirculation during excessive hemorrhage using fluid therapy. In Vivo 17 (2003) 129-136
70. Morishita H., Yamakawa T., Matsusue T., Kusuyama T., Sameshima-Aruga R., Hirose J., et al. Novel factor Xa and plasma kallikrein inhibitory activities of the second Kunitz-type inhibitory domain of urinary trypsin inhibitor. Thromb Res 73 (1994) 193-204
71. Kanayama N., Maehara K., She L., Belayet H., Khatun S., Tokunaga N., et al. Urinary trypsin inhibitor suppresses vascular smooth muscle contraction by inhibition of Ca2+ influx. Biochim Biophys Acta 1381 (1998) 139-146
72. Bono F., Lamarche I., and Herbert J. Induction of vascular smooth muscle cell growth by selective activation of the proteinase activated receptor-2 (PAR-2). Biochem Biophys Res Commun 241 (1997) 762-764
73. Olear T., and Nouza K. Thrombin and trypsin receptors: The same mechanism of signaling on cellular surfaces. Bratisl Lek Listy 100 (1999) 75-79
74. Cottrell G. Protease activated receptors: The role of cell surface proteolysis in signaling. Essays Biochem 38 (2002) 169-183
75. Miike S., McWilliam A., and Kita H. Trypsin induces activation and inflammatory mediator release from human eosinophils through protease-activated receptor-2. J Immunol 167 (2001) 6615-6622
76. Shibutani Y., and Kunihiro Y. Preventive effects of urinastatin on tissue degradation. Yakuri Chiryo 14 (1986) 6057-6072
77. Coelho A., Ossovskaya V., and Bunnett N. Proteinase-activated receptor-2: Physiological and pathophysiological roles. Curr Med Chem Cardiovasc Hematol Agents 1 (2003) 61-72
78. Rohatgi T., Sedehizade F., Reymann K., and Reiser G. Protease-activated receptors in neuronal development, neurodegeneration, and neuroprotection: Thrombin as signaling molecule in the brain. Neuroscientist 10 (2004) 501-512
79. Day J., Punjabi P., Randi A., Haskard D., Landis R., and Taylor K. Clinical inhibition of the seven-transmembrane thrombin receptor (PAR1) by intravenous aprotinin during cardiothoracic surgery. Circulation 110 (2004) 2597-2600
80. Steinberg S. The cardiovascular actions of protease-activated receptors. Mol Pharmacol 67 (2005) 2-11
81. Kher A., Meldrum K., Hile K., Wang M., Tsai B., Turrentine M., et al. Aprotinin improves kidney function and decreases tubular cell apoptosis and proapoptotic signaling after renal ischemia-reperfusion. J Thorac Cardiovasc Surg 130 (2005) 662-669
82. Luo J., Kamata H., and Karin M. IKK/NF-κB signaling: Balancing life and death, a new approach to cancer therapy. J Clin Invest 115 (2005) 2625-2632
83. Kanayama N., el Maradny E., Yamamoto N., Tokunaga N., Maehara K., and Terao T. Urinary trypsin inhibitor: A new drug to treat preterm labor: A comparative study with ritodrine. Eur J Obstet Gynecol Reprod Biol 67 2 (1996) 133-138
84. Masuda J., Suzuki K., Satoh A., Kojima-Aikawa K., Nakanishi K., Kuroda K., et al. Matsumoto I. Beta-2-glycoprotein I and urinary trypsin inhibitor levels in the plasma of pregnant and postpartum women. Thromb Res 117 (2006) 255-261
85. Kobayashi H., Suzuki M., Hirashima Y., and Terao T. The protease inhibitor bikunin, a novel anti-metastatic agent. Biol Chem 384 (2003) 749-754
86. Suzuki M., Kobayashi H., Tanaka Y., Hirashima Y., Kanayama N., Takei Y., et al. Suppression of invasion and peritoneal carcinomatosis of ovarian cancer cell line by over-expression of bikunin. Int J Cancer 104 (2003) 289-302
87. Hirashima Y., Suzuki M., and Kobayashi H. Suppression of cancer invasion and metastasis in human ovarian cancer cells transfected with UTI gene. Surg Trauma Immunol Respon 10 (2001) 30-36
88. Kobayashi H., Sugino D., She M., Ohi H., Hirashima Y., Shinohara H., et al. A bifunctional hybrid molecule of the amino-terminal fragment of urokinase and domain II of bikunin efficiently inhibits tumor cell invasion and metastasis. Eur J Biochem 253 (1998) 817-826
89. Takubo T., Kumura T., Nakamae H., Aoyama Y., Koh K., Ohta K., et al. Urinary trypsin inhibitor levels in the urine of patients with haematological malignancies. Haematologia (Budap) 31 (2001) 267-272
90. Endo Y. Antishock action of ulinastatin. Surg Trauma Immunol Respon 12 (2003) 29-38
91. Nakatani K., Takeshita S., Tsujimoto H., Kawamura Y., and Sekine I. Inhibitory effect of serine protease inhibitors on neutrophil-mediated endothelial cell injury. J Leukoc Biol 69 (2001) 241-247
92. Cochrane C., Unanue E., and Dixon F. A role of polymorphonuclear leukocyte and complement in nephrotoxic nephritis. J Exp Med 122 (1965) 99-116
93. Yamaguchi Y., Ohshiro H., Nagao Y., Odawara K., Okabe K., Hidaka H., et al. Urinary trypsin inhibitor reduces C-X-C chemokine production in rat liver ischemia/reperfusion. J Surg Res 94 (2000) 107-115
94. Suzuki M., Kobayashi H., Tanaka Y., Hirashima Y., and Terao T. Structure and function analysis of urinary trypsin inhibitor (UTI): Identification of binding domains and signaling property of UTI by analysis of truncated proteins. Biochim Biophys Acta 1547 (2001) 26-36
95. Koizumi R., Kanai H., Maezawa A., Kanda T., Nojima Y., and Naruse T. Therapeutic effects of ulinastatin on experimental crescentic glomerulonephritis in rats. Nephron 84 (2000) 347-353
96. Wakayama T., Mizushima S., Hirose J., and Iseki S. Urinary trypsin inhibitor: Production in the liver and reabsorption in the kidney of the rat. Acta Histochem Cytochem 29 (1996) 227-236
97. Nakakuki M., Yamasaki F., Shinkawa T., Kudo M., Watanabe M., and Mizota M. Protective effect of human ulinastatin against gentamicin-induced acute renal failure in rats. Can J Physiol Pharmacol 74 (1996) 104-111
98. Chao J., Stallone J., Liang Y., Chen L., Wang D., and Chao L. Kallistatin is a potent new vasodilator. J Clin Invest 100 (1997) 11-17
99. Yoshino M. Contribution of TNF-alpha- and IL-6 in hepatic ischemia reperfusion injury. Toho Igakkai Zasshi 42 (1996) 530-543
100. Takada K., Komori M., Notoya A., Tomizawa Y., and Ozaki M. Effect of ulinastatin on microcirculation during excessive hemorrhage using fluid therapy. In Vivo 17 (2003) 129-136
101. Takahashi M., Sawaguchi T., Sawaguchi A., and Suzuki T. The cytoprotective effect of protease inhibitor on programmed cell death of endothelial cell. Tokyo Joshi Ika Daigaku Zasshi 71 (2001) 669-678
102. Kaplan A., Silverberg M., Dunn J., and Ghebrehiwet B. Interaction of the clotting, kinin forming, complement, and fibrinolytic pathways in inflammation. Ann NY Acad Sci 389 (1982) 25-38
103. Collier A., Patrick A., Hepburn D., Bell D., Jackson M., Dawes J., et al. Leucocyte mobilization and release of neutrophil elastase following acute insulin-induced hypoglycaemia in normal humans. Diabet Med 7 (1990) 506-509
104. Collier A., Jackson M., Bell D., Patrick A., Matthews D., Young R., et al. Neutrophil activation detected by increased neutrophil elastase activity in type 1 (insulin-dependent) diabetes mellitus. Diabetes Res 10 (1989) 135-138
105. Hirano T., and Manabe T. Human urinary trypsin inhibitor, urinastatin, prevents pancreatic injuries induced by pancreaticobiliary duct obstruction with caerulein stimulation and systemic hypotension in the rat. Arch Surg 128 (1993) 1322-1329